These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 12627673)

  • 1. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in the development of anticoagulant and antithrombotic drugs.
    Fareed J; Hoppensteadt D; Walenga JM; Bick RL
    Med Clin North Am; 1994 May; 78(3):713-31. PubMed ID: 8170266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Garcia DA; Baglin TP; Weitz JI; Samama MM
    Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successors to heparin: new antithrombotic agents.
    Turpie AG
    Am Heart J; 1997 Nov; 134(5 Pt 2):S71-7. PubMed ID: 9396637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation.
    Spadarella G; Di Minno A; Donati MB; Mormile M; Ventre I; Di Minno G
    Blood Rev; 2020 Jan; 39():100613. PubMed ID: 31471127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies on a low molecular weight heparin.
    Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
    Thromb Res; 1996; 81(2 Suppl):S1-27. PubMed ID: 8822124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.